ArticleFrontiers in immunology2026

Multi-omics profiling identifies ADAM9 as a key efferocytosis driver in lung adenocarcinoma.

Guofu Lin et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.